162 related articles for article (PubMed ID: 19664662)
41. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
[TBL] [Abstract][Full Text] [Related]
42. Differential in vitro inhibitory activity against HIV-1 of alpha-(1-3)- and alpha-(1-6)-D-mannose specific plant lectins: implication for microbicide development.
Saïdi H; Nasreddine N; Jenabian MA; Lecerf M; Schols D; Krief C; Balzarini J; Bélec L
J Transl Med; 2007 Jun; 5():28. PubMed ID: 17565674
[TBL] [Abstract][Full Text] [Related]
43. Characterization of HIV-2 chimeric viruses unable to use CCR5 and CXCR4 coreceptors.
Santos-Costa Q; Mansinho K; Moniz-Pereira J; Azevedo-Pereira JM
Virus Res; 2009 Jun; 142(1-2):41-50. PubMed ID: 19200444
[TBL] [Abstract][Full Text] [Related]
44. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides.
Van Herrewege Y; Morellato L; Descours A; Aerts L; Michiels J; Heyndrickx L; Martin L; Vanham G
J Antimicrob Chemother; 2008 Apr; 61(4):818-26. PubMed ID: 18270220
[TBL] [Abstract][Full Text] [Related]
45. Down-regulation of CXCR4 expression by SDF-KDEL in CD34(+) hematopoietic stem cells: An anti-human immunodeficiency virus strategy.
Zhang JC; Sun L; Nie QH; Huang CX; Jia ZS; Wang JP; Lian JQ; Li XH; Wang PZ; Zhang Y; Zhuang Y; Sun YT; Bai X
J Virol Methods; 2009 Oct; 161(1):30-7. PubMed ID: 19463855
[TBL] [Abstract][Full Text] [Related]
46. Synergistic inhibition of HIV-1 infection by combinations of soluble polyanions with other potential microbicides.
Gantlett KE; Weber JN; Sattentau QJ
Antiviral Res; 2007 Sep; 75(3):188-97. PubMed ID: 17408760
[TBL] [Abstract][Full Text] [Related]
47. Biological and physical characterization of the X4 HIV-1 suppressive factor secreted by LPS-stimulated human macrophages.
Mikulak J; Gianolini M; Versmisse P; Pancino G; Lusso P; Verani A
Virology; 2009 Jul; 390(1):37-44. PubMed ID: 19447459
[TBL] [Abstract][Full Text] [Related]
48. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.
Chong BF; Mohan C
Expert Opin Ther Targets; 2009 Oct; 13(10):1147-53. PubMed ID: 19670960
[TBL] [Abstract][Full Text] [Related]
49. Targeting HIV-1 through molecular modeling and docking studies of CXCR4: leads for therapeutic development.
Singh S; Malik BK; Sharma DK
Chem Biol Drug Des; 2007 Mar; 69(3):191-203. PubMed ID: 17441905
[TBL] [Abstract][Full Text] [Related]
50. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
[TBL] [Abstract][Full Text] [Related]
51. Rapamycin enhances aplaviroc anti-HIV activity: implications for the clinical development of novel CCR5 antagonists.
Latinovic O; Heredia A; Gallo RC; Reitz M; Le N; Redfield RR
Antiviral Res; 2009 Jul; 83(1):86-9. PubMed ID: 19501260
[TBL] [Abstract][Full Text] [Related]
52. Specific interactions between the viral coreceptor CXCR4 and the biguanide-based compound NB325 mediate inhibition of human immunodeficiency virus type 1 infection.
Thakkar N; Pirrone V; Passic S; Zhu W; Kholodovych V; Welsh W; Rando RF; Labib ME; Wigdahl B; Krebs FC
Antimicrob Agents Chemother; 2009 Feb; 53(2):631-8. PubMed ID: 19047650
[TBL] [Abstract][Full Text] [Related]
53. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of human immunodeficiency virus type 1 (HIV-1) nuclear import via Vpr-Importin alpha interactions as a novel HIV-1 therapy.
Suzuki T; Yamamoto N; Nonaka M; Hashimoto Y; Matsuda G; Takeshima SN; Matsuyama M; Igarashi T; Miura T; Tanaka R; Kato S; Aida Y
Biochem Biophys Res Commun; 2009 Mar; 380(4):838-43. PubMed ID: 19338763
[TBL] [Abstract][Full Text] [Related]
55. HIV-1 tropism, disease progression, and clinical management.
Burger H; Hoover D
J Infect Dis; 2008 Oct; 198(8):1095-7. PubMed ID: 18783314
[No Abstract] [Full Text] [Related]
56. HIV-1 infection of human penile explant tissue and protection by candidate microbicides.
Fischetti L; Barry SM; Hope TJ; Shattock RJ
AIDS; 2009 Jan; 23(3):319-28. PubMed ID: 19114867
[TBL] [Abstract][Full Text] [Related]
57. Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV.
Shimizu N; Tanaka A; Oue A; Mori T; Ohtsuki T; Apichartpiyakul C; Uchiumi H; Nojima Y; Hoshino H
AIDS; 2009 Apr; 23(7):761-9. PubMed ID: 19307942
[TBL] [Abstract][Full Text] [Related]
58. New developments in HIV drug resistance.
Cane PA
J Antimicrob Chemother; 2009 Sep; 64 Suppl 1():i37-40. PubMed ID: 19675018
[TBL] [Abstract][Full Text] [Related]
59. Current tests to evaluate HIV-1 coreceptor tropism.
Rose JD; Rhea AM; Weber J; Quiñones-Mateu ME
Curr Opin HIV AIDS; 2009 Mar; 4(2):136-42. PubMed ID: 19339953
[TBL] [Abstract][Full Text] [Related]
60. Human glutaredoxin-1 catalyzes the reduction of HIV-1 gp120 and CD4 disulfides and its inhibition reduces HIV-1 replication.
Auwerx J; Isacsson O; Söderlund J; Balzarini J; Johansson M; Lundberg M
Int J Biochem Cell Biol; 2009 Jun; 41(6):1269-75. PubMed ID: 19038358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
